
Outlook Therapeutics has announced the Scottish Medicines Consortium (SMC) approval of Lytenava (bevacizumab gamma) for the treatment of wet age-related …
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
FibroFind appoints Professor Andrew Fisher as Chief Medical Officer

